INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share on the same day [3] Group 2: Legal Actions - Pomerantz LLP is actively seeking claims from investors of Senti Biosciences, indicating a potential class action lawsuit [1][2] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [4]